Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

jrh34 Aug. 24 at 7:51 PM

$CRDF I would say today's conference was bullish for both NMS and CRDF. There's plenty of money for both companies selling Onvasertib rights to a partner like $PFE - a good day for everyone, well except for anyone short.

0 · Reply

STOCKPICKERTRADER Aug. 24 at 7:24 PM

$PFE nice to see https://finance.yahoo.com/markets/stocks/articles/pfizer-stock-wall-street-sees-150011046.html

0 · Reply

Makingmillions192 Aug. 24 at 6:47 PM

$LEXX Success in investing is more of a psychological issue than a math issue. The math is here. The patience is the hard part. If you need a guiding star on why we are on the cusp of transformative success read this: While the market gets distracted by low-volume noise, the fundamentals just got wildly de-risked. Today’s Animal Study #2 data proved DehydraTECH 3.0 delivers staggering absorption gains (+4,552% for Retatrutide, 1.65% bioavailability for Amycretin) in solid oral tablets while outperforming Novo's SNAC using open-source binders. That scientifically validates our entire thesis right before Human Study #7 drops. We aren't just holding for a study readout—we're waiting on multi-week, steady-state human tablet data that could force Big Pharma into major licensing deals. Stay disciplined. $LLY $NVO $PFE $MRK

0 · Reply

doubleuptwice Aug. 24 at 5:59 PM

$PFE close above 28.16

2 · Reply

Loudermilk64 Aug. 24 at 4:03 PM

$PFE green?

0 · Reply

Loudermilk64 Aug. 24 at 3:47 PM

$PFE going to do another gap up by Wednesday probably…

0 · Reply

Chickenstick1 Aug. 24 at 3:40 PM

$PFE Could be a good, much cheaper, way to play the personalized MRNA vaccine for cancer. The co does own some critical IP that allow them to bring a competitor to market.

0 · Reply

AJeaton91 Aug. 24 at 1:59 PM

$PFE added very lightly here, looking to play the turn around story over the next couple years.

1 · Reply

nimii Aug. 24 at 1:44 PM

$PFE 😠

0 · Reply

Outcomes Aug. 24 at 1:19 PM

$PFE $MRNA $MRK $JNJ $IBRX ....mRNA BAD. Sudden deaths, myocarditis, turbo-cancers....compromised immunity, etc. SAVE THE CHILDREN. 🙏 https://x.com/ValerieAnne1970/status/2091646664352133205?s=20

0 · Reply

Pfizer, Valneva announce EMA validation for PF-07307405 MAA

PFE VALN

Aug 14, 2026, 1:45 PM EDT - 10 days ago

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Aug 14, 2026, 11:46 AM EDT - 10 days ago

Closed Pfizer biopharma facility in Everett gets a new lease on life

Aug 14, 2026, 11:11 AM EDT - 10 days ago

Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money

Aug 14, 2026, 1:00 AM EDT - 10 days ago

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

VALN

2026-08-07T11:40:49.000Z - 17 days ago

Pfizer price target lowered to $31 from $35 at Guggenheim

PFE

2026-08-05T10:45:23.000Z - 19 days ago

Pfizer price target raised to $27 from $26 at BofA

PFE

Aug 4, 2026, 10:00 AM EDT - 20 days ago

Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 20 days ago

Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 20 days ago

Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 20 days ago

Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 7:24 AM EDT - 20 days ago

Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:13 AM EDT - 20 days ago

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Aug 4, 2026, 7:12 AM EDT - 20 days ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

BNTX

2026-08-04T10:52:17.000Z - 20 days ago

Pfizer reports Q2 adjusted EPS 77c, consensus 68c

PFE

Aug 4, 2026, 6:52 AM EDT - 20 days ago

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Aug 4, 2026, 6:45 AM EDT - 20 days ago

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Jul 30, 2026, 7:48 AM EDT - 25 days ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Jul 30, 2026, 6:45 AM EDT - 25 days ago

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Jul 29, 2026, 4:30 PM EDT - 26 days ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BNTX

Jul 22, 2026, 4:48 PM EDT - 4 weeks ago

Pfizer's prostate cancer drug combination gets US FDA priority review

Jul 22, 2026, 4:30 PM EDT - 4 weeks ago

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Jul 21, 2026, 7:10 PM EDT - 4 weeks ago

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

LLY

Jul 16, 2026, 1:39 PM EDT - 5 weeks ago

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Jul 10, 2026, 11:23 AM EDT - 6 weeks ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Jul 6, 2026, 10:00 AM EDT - 7 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jun 29, 2026, 4:43 PM EDT - 2 months ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Jun 29, 2026, 1:20 AM EDT - 2 months ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 24, 2026, 3:52 PM EDT - 2 months ago

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 2:10 PM EDT - 2 months ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 10:51 AM EDT - 2 months ago

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 23, 2026, 12:10 PM EDT - 2 months ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 22, 2026, 4:43 PM EDT - 2 months ago

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:30 PM EDT - 2 months ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 2:32 PM EDT - 2 months ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Jun 18, 2026, 6:52 AM EDT - 2 months ago

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Chief Financial Officer Transition

Jun 10, 2026, 7:56 AM EDT - 2 months ago

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 9, 2026, 2:07 PM EDT - 2 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

Jun 9, 2026, 3:20 AM EDT - 2 months ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:45 AM EDT - 2 months ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update

Jun 6, 2026, 9:06 AM EDT - 2 months ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:00 AM EDT - 2 months ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 6:40 AM EDT - 2 months ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 10:00 AM EDT - 3 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 31, 2026, 8:00 AM EDT - 3 months ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 30, 2026, 8:00 AM EDT - 3 months ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 29, 2026, 8:00 AM EDT - 3 months ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 28, 2026, 11:10 PM EDT - 3 months ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 7:19 PM EDT - 3 months ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:00 PM EDT - 3 months ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 3 months ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 27, 2026, 10:00 AM EDT - 3 months ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

jrh34 Aug. 24 at 7:51 PM

0 · Reply

STOCKPICKERTRADER Aug. 24 at 7:24 PM

$PFE nice to see https://finance.yahoo.com/markets/stocks/articles/pfizer-stock-wall-street-sees-150011046.html

0 · Reply

Makingmillions192 Aug. 24 at 6:47 PM

0 · Reply

doubleuptwice Aug. 24 at 5:59 PM

$PFE close above 28.16

2 · Reply

Loudermilk64 Aug. 24 at 4:03 PM

$PFE green?

0 · Reply

Loudermilk64 Aug. 24 at 3:47 PM

$PFE going to do another gap up by Wednesday probably…

0 · Reply

Chickenstick1 Aug. 24 at 3:40 PM

$PFE Could be a good, much cheaper, way to play the personalized MRNA vaccine for cancer. The co does own some critical IP that allow them to bring a competitor to market.

0 · Reply

AJeaton91 Aug. 24 at 1:59 PM

$PFE added very lightly here, looking to play the turn around story over the next couple years.

1 · Reply

nimii Aug. 24 at 1:44 PM

$PFE 😠

0 · Reply

Outcomes Aug. 24 at 1:19 PM

$PFE $MRNA $MRK $JNJ $IBRX ....mRNA BAD. Sudden deaths, myocarditis, turbo-cancers....compromised immunity, etc. SAVE THE CHILDREN. 🙏 https://x.com/ValerieAnne1970/status/2091646664352133205?s=20

0 · Reply

Makingmillions192 Aug. 24 at 1:18 PM

$LEXX Holy shit this is massive. • Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study • Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated • Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs $LLY $NVO $PFE $AMGN

0 · Reply

NorthOfSouth Aug. 24 at 11:41 AM

$PFE 28.70 today

1 · Reply

Loudermilk64 Aug. 24 at 11:31 AM

$PFE forgot the $TEM tag. They wouldn’t be able to make it without the Tempus and the Personalis. $MRNA $JNJ $MRK .

0 · Reply

Loudermilk64 Aug. 24 at 11:29 AM

$PFE it’s been selling around this price for the past year. Maybe the shorts will offer a couple bucks over the 52 wk high, 30?, for all the bag holders?

0 · Reply

Quantumup Aug. 24 at 11:11 AM

Morgan Stanley🏁 $QTTB and said -- We initiate coverage of Q32 Bio (QTTB) with an Overweight rating and a $34 price target. $LLY $PFE ABBV NKTR SNY Here's what Morgan Stanley went on to say in its initiation report: https://x.com/Quantumup1/status/2091845523888079173?s=20

0 · Reply

Outcomes Aug. 24 at 10:01 AM

$IBRX $MRNA $MRK $PFE $JNJ ……🤔 monkey business https://x.com/jsolomonreports/status/2091501968359395399?s=46

2 · Reply

Szepen Aug. 24 at 7:54 AM

$SLS If Regal goes under 0,50 HR that will make so much splash... $MRNA and $PFE created an environment that will drive a 100+ opener easily if Regal succeed... The CEO will go to Fox News again for sure...

1 · Reply

Diehard777 Aug. 24 at 4:17 AM

$PFE 💥💥💥

0 · Reply

USAEquityResearch Aug. 23 at 6:05 PM

$PFE 📊 USAEquityResearch ▲ 28.07 (+1.01%) Trend: Bullish 📈 RSI (14): 77.9 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: normal 📌 Key Levels Resistance: 28.24 | Support: 24.67 20-MA: 26.30 | 50-MA: 25.11 💼 Fundamentals Mkt Cap: $159.99B P/E (TTM): 36.9 | Fwd P/E: 9.7 FCF: $12.49B (2.19/sh) Total Debt: $63.48B D/E: 74.25 📉 Options (exp 2026-08-28) ATM IV: 26.1% | Skew: -1.6% (balanced) P/C Ratio: 0.32 🐂 Bullish lean Max Pain: 26.00 Call wall: 28.50 | Put wall: 28.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/PFE

1 · Reply

AnotherVoid Aug. 23 at 4:27 PM

$PFE Weekly uptrending channel:

0 · Reply

Ernestuxas Aug. 23 at 2:34 PM

$PFE solid weekly close. clear entry point

0 · Reply

Outcomes Aug. 23 at 11:11 AM

$IBRX $MRNA $PFE $JNJ $MRK .....in other than cancer news, but same mRNA BAD news: https://x.com/CBSMornings/status/2091247789204226076?s=20

2 · Reply

Market Cap	159.99B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	9.11
Forward PE	9.33
Profit Margin	12.42%
Debt to Equity Ratio	0.74

Volume	22,241,654
Avg Vol	44,625,605
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	84%
Beta	0.34
Analysts	Sell
Price Target	$28.60